A Randomized, Double-Blind, Single Center Cohort Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of a Single 1200MG IV Dose of Oritavancin in Healthy Volunteers

Trial Profile

A Randomized, Double-Blind, Single Center Cohort Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of a Single 1200MG IV Dose of Oritavancin in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Oritavancin (Primary)
  • Indications Anthrax; Bacteraemia; Clostridium infections; Gram-positive infections; Skin and soft tissue infections
  • Focus Adverse reactions
  • Sponsors The Medicines Company
  • Most Recent Events

    • 19 Apr 2016 Status changed from recruiting to completed.
    • 04 Nov 2015 Planned End Date changed from 1 Nov 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.
    • 04 Nov 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top